Avotres Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4M

  • Investors
  • 3

Avotres General Information

Description

Operator of a biotechnology company intended to develop and commercialize transformational therapies and drugs in autoimmune diseases, cancers, and transplantation. The company develops drugs using science built on elucidating the fundamental mechanism of peripheral self-nonself discrimination after thymic negative selection in the context of immune self-tolerance to address the common root cause of autoimmune diseases, enabling healthcare professionals and doctors to find a cure for cancer and other related diseases.

Contact Information

Website
www.avotres.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 140 East Hanover Avenue
  • Cedar Knolls, NJ 07927
  • United States
+1 (800)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences, Oncology
Corporate Office
  • 140 East Hanover Avenue
  • Cedar Knolls, NJ 07927
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avotres Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 04-May-2023 $4M Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) Completed Clinical Trials - Phase 2
1. Seed Round 24-Feb-2021 $4M $4M Completed Clinical Trials - Phase 2
To view Avotres’s complete valuation and funding history, request access »

Avotres Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-4
Series A-3
Series A-2 1,285,220 $0.000010 8% $0.52 $0.52 1x $0.52 1.31%
Series A-1 21,340,539 $0.000010 8% $0.67 $0.67 1x $0.67 21.68%
To view Avotres’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Avotres Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • Pending

  • Expiring in next 12 mo

Avotres Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220378825-A1 A method for treating multiple sclerosis with peptide-loaded dendritic cells Active 31-May-2021
EP-4346852-A1 A therapeutic preparation and methods for treating autoimmune diseases Inactive 31-May-2021
EP-4346852-A4 A therapeutic preparation and methods for treating autoimmune diseases Inactive 31-May-2021
WO-2022256257-A1 A therapeutic preparation and methods for treating autoimmune diseases Inactive 31-May-2021
US-11779607-B2 Detection of a defect on hla-e restricted cd8+ t regulatory cells Active 31-May-2021 A61K35/17
To view Avotres’s complete patent history, request access »

Avotres Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avotres Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Photon Fund (China) Venture Capital Minority
Proxima Capital Venture Capital Minority
Foothill Ventures Venture Capital Minority
To view Avotres’s complete investors history, request access »

Ready to get started?

Request a free trial

Avotres FAQs

  • When was Avotres founded?

    Avotres was founded in 2016.

  • Where is Avotres headquartered?

    Avotres is headquartered in Cedar Knolls, NJ.

  • What is the size of Avotres?

    Avotres has 7 total employees.

  • What industry is Avotres in?

    Avotres’s primary industry is Drug Discovery.

  • Is Avotres a private or public company?

    Avotres is a Private company.

  • What is Avotres’s current revenue?

    The current revenue for Avotres is .

  • How much funding has Avotres raised over time?

    Avotres has raised $23.4M.

  • Who are Avotres’s investors?

    Photon Fund (China), Proxima Capital, and Foothill Ventures have invested in Avotres.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process